Incyte Corporation (FRA:ICY)

Market Cap	17.12B +23.0%
Revenue (ttm)	4.38B +21.2%
Net Income	1.10B +3,845.0%
EPS	5.46 +4,173.3%
Shares Out	n/a
PE Ratio	15.62
Forward PE	13.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	133
Open	86.38
Previous Close	87.02
Day's Range	86.38 - 86.38
52-Week Range	49.00 - 95.56
Beta	n/a
RSI	50.73
Earnings Date	Feb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,844
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ICY

Financial Performance

In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.

Financial numbers in USD